Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer-journals/emerging-predictive-biomarkers-of-response-to-platinum-therapy-in-ZQbtNX2sBw
References (58)
-
T. Byrski, T. Huzarski, R. Dent, E. Marczyk, M. Jasiówka, J. Gronwald, Jerzy Jakubowicz, C. Cybulski, R. Wiśniowski, D. Godlewski, J. Lubiński, S. Narod (2014)
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patientsBreast Cancer Research and Treatment, 147
-
G. Morris, S. Naidu, A. Topham, F. Guiles, Yihuan Xu, P. Mccue, G. Schwartz, P. Park, A. Rosenberg, K. Brill, E. Mitchell (2007)
Differences in breast carcinoma characteristics in newly diagnosed African–American and Caucasian patientsCancer, 110
-
M. Ray, B. Polite (2010)
Triple-Negative Breast Cancers: A View From 10,000 FeetThe Cancer Journal, 16
-
K. Bauer, Monica Brown, R. Cress, C. Parise, V. Caggiano (2007)
Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 109
-
Z. Wang, N. Birkbak, A. Culhane, R. Drapkin, Aquila Fatima, Ruiyang Tian, Matthew Schwede, K. Alsop, Kathryn Daniels, H. Piao, Joyce Liu, D. Etemadmoghadam, A. Miron, H. Salvesen, G. Mitchell, A. deFazio, John Quackenbush, R. Berkowitz, J. Iglehart, D. Bowtell, U. Matulonis (2012)
Profiles of Genomic Instability in High-Grade Serous Ovarian Cancer Predict Treatment OutcomeClinical Cancer Research, 18
-
E. Ibrahim, M. Al-Foheidi, M. Al-Mansour, Ghieth Kazkaz (2014)
The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysisBreast Cancer Research and Treatment, 148
-
Yasmin Issa-Nummer, S. Darb-Esfahani, S. Loibl, G. Kunz, V. Nekljudova, I. Schrader, B. Sinn, H. Ulmer, R. Kronenwett, M. Just, T. Kühn, K. Diebold, M. Untch, F. Holms, J. Blohmer, J. Habeck, M. Dietel, F. Overkamp, P. Krabisch, G. Minckwitz, C. Denkert (2013)
Prospective Validation of Immunological Infiltrate for Prediction of Response to Neoadjuvant Chemotherapy in HER2-Negative Breast Cancer – A Substudy of the Neoadjuvant GeparQuinto TrialPLoS ONE, 8
-
O. Moore, F. Foote (1949)
The relatively favorable prognosis of medullary carcinoma of the breastCancer, 2
-
G. Minckwitz, K. Timms, M. Untch, E. Elkin, P. Fasching, A. Schneeweiss, C. Salat, M. Rezai, J. Blohmer, D. Zahm, C. Jackisch, B. Gerber, P. Klare, S. Kümmel, H. Eidtmann, S. Paepke, J. Reid, V. Nekljudova, A. Hartman, S. Loibl (2015)
Prediction of pathological complete response (pCR) by Homologous Recombination Deficiency (HRD) after carboplatin-containing neoadjuvant chemotherapy in patients with TNBC: Results from GeparSixto.Journal of Clinical Oncology, 33
-
M. Cheang, D. Voduc, C. Bajdik, S. Leung, S. McKinney, S. Chia, C. Perou, T. Nielsen (2008)
Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative PhenotypeClinical Cancer Research, 14
-
C. Denkert, G. Minckwitz, J. Brase, B. Sinn, S. Gade, R. Kronenwett, B. Pfitzner, C. Salat, S. Loi, W. Schmitt, C. Schem, K. Fisch, S. Darb-Esfahani, K. Mehta, C. Sotiriou, S. Wienert, P. Klare, F. André, F. Klauschen, J. Blohmer, K. Krappmann, Marcus Schmidt, H. Tesch, S. Kümmel, P. Sinn, C. Jackisch, M. Dietel, T. Reimer, M. Untch, S. Loibl (2015)
Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 9
-
Xiaolan Hu, H. Stern, Lin Ge, Carol O'brien, L. Haydu, C. Honchell, Peter Haverty, B. Peters, Thomas Wu, L. Amler, J. Chant, D. Stokoe, M. Lackner, G. Cavet (2009)
Genetic Alterations and Oncogenic Pathways Associated with Breast Cancer SubtypesMolecular Cancer Research, 7
-
K. Timms, A. Chagpar, V. Wali, V. Bossuyt, J. Reid, A. Gutin, C. Neff, E. Hofstatter, J. Lanchbury, L. Pusztai (2015)
Reproducibility of homologous recombination deficiency (HRD) scores in biopsies of triple negative breast cancer (TNBC) tumors.Journal of Clinical Oncology, 33
-
G. Minckwitz, A. Schneeweiss, S. Loibl, C. Salat, C. Denkert, M. Rezai, J. Blohmer, C. Jackisch, S. Paepke, B. Gerber, D. Zahm, S. Kümmel, H. Eidtmann, P. Klare, J. Huober, S. Costa, H. Tesch, C. Hanusch, J. Hilfrich, F. Khandan, P. Fasching, B. Sinn, K. Engels, K. Mehta, V. Nekljudova, M. Untch (2014)
Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial.The Lancet. Oncology, 15 7
-
M. Telli, K. Timms, J. Reid, C. Neff, V. Abkevich, A. Gutin, Zaina Sangale, D. Illiev, Joshua Jones, B. Hennessy, J. Lanchbury, G. Mills, A. Hartman, J. Ford (2015)
Combined Homologous Recombination Deficiency (HRD) scores and response to neoadjuvant platinum-based chemotherapy in triple-negative and/or BRCA1/2 mutation-associated breast cancer.Journal of Clinical Oncology, 33
-
C. Gu-Trantien, S. Loi, S. Garaud, C. Equeter, M. Libin, A. Wind, M. Ravoet, H. Buanec, C. Sibille, G. Manfouo-Foutsop, I. Veys, Benjamin Haibe-Kains, S. Singhal, S. Michiels, F. Rothé, R. Salgado, H. Duvillier, M. Ignatiadis, C. Desmedt, D. Bron, D. Larsimont, M. Piccart, C. Sotiriou, K. Willard-Gallo (2013)
CD4⁺ follicular helper T cell infiltration predicts breast cancer survival.The Journal of clinical investigation, 123 7
-
M. Telli, Kirstin Jensen, V. Abkevich, A. Hartman, S. Vinayak, J. Lanchbury, A. Gutin, K. Timms, J. Ford (2012)
Abstract PD09-04: Homologous Recombination Deficiency (HRD) score predicts pathologic response following neoadjuvant platinum-based therapy in triple-negative and BRCA1/2 mutation-associated breast cancer (BC)Cancer Research, 72
-
H. Rugo, O. Olopade, A. Demichele, L. Veer, M. Buxton, N. Hylton, D. Yee, A. Chien, A. Wallace, I-Spy PI's, J. Lyandres, S. Davis, A. Sanil, D. Berry, L. Esserman (2013)
Abstract S5-02: Veliparib/carboplatin plus standard neoadjuvant therapy for high-risk breast cancer: First efficacy results from the I-SPY 2 TRIALCancer Research, 73
-
T. Popova, Elodie Manié, Guillaume Rieunier, V. Caux‐Moncoutier, Carole Tirapo, T. Dubois, O. Delattre, B. Sigal‐Zafrani, M. Bollet, M. Longy, C. Houdayer, X. Sastre-Garau, A. Vincent-Salomon, D. Stoppa-Lyonnet, M. Stern (2012)
Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.Cancer research, 72 21
-
B. Lehmann, Joshua Bauer, X. Chen, M. Sanders, A. Chakravarthy, Y. Shyr, J. Pietenpol (2011)
Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.The Journal of clinical investigation, 121 7
-
A. González-Angulo, K. Timms, Shuying Liu, Huiqin Chen, J. Litton, J. Potter, J. Lanchbury, K. Stemke‐Hale, B. Hennessy, B. Arun, G. Hortobagyi, K. Do, G. Mills, F. Meric-Bernstam (2011)
Incidence and Outcome of BRCA Mutations in Unselected Patients with Triple Receptor-Negative Breast CancerClinical Cancer Research, 17
-
B. Hennessy, S. Giordano, K. Broglio, Z. Duan, J. Trent, T. Buchholz, G. Babiera, G. Hortobagyi, V. Valero (2006)
Biphasic metaplastic sarcomatoid carcinoma of the breast.Annals of oncology : official journal of the European Society for Medical Oncology, 17 4
-
R. Siegel, K. Miller, A. Jemal (2015)
Cancer statistics, 2015CA: A Cancer Journal for Clinicians, 65
-
L. Carey, E. Winer, G. Viale, D. Cameron, L. Gianni (2010)
Triple-negative breast cancer: disease entity or title of convenience?Nature Reviews Clinical Oncology, 7
-
C. Perou, T. Sørlie, M. Eisen, M. Rijn, S. Jeffrey, Christian Rees, J. Pollack, D. Ross, H. Johnsen, L. Akslen, Ø. Fluge, Alexander Pergamenschikov, Cheryl Williams, Shirley Zhu, P. Lønning, A. Børresen-Dale, P. Brown, D. Botstein (2000)
Molecular portraits of human breast tumoursNature, 406
-
H. Masuda, K. Baggerly, Ying Wang, Ya Zhang, A. González-Angulo, F. Meric-Bernstam, V. Valero, B. Lehmann, J. Pietenpol, G. Hortobagyi, W. Symmans, N. Ueno (2013)
Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesClinical Cancer Research, 19
-
M. Ono, H. Tsuda, C. Shimizu, Sohei Yamamoto, T. Shibata, H. Yamamoto, T. Hirata, K. Yonemori, M. Ando, K. Tamura, N. Katsumata, T. Kinoshita, Y. Takiguchi, H. Tanzawa, Y. Fujiwara (2012)
Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancerBreast Cancer Research and Treatment, 132
-
A. Tutt, P. Ellis, L. Kilburn, Cheryl Gilett, S. Pinder, J. Abraham, S. Barrett, P. Barrett-Lee, S. Chan, M. Cheang, M. Dowsett, Lisa Fox, P. Gazinska, A. Grigoriadis, A. Gutin, C. Harper-wynne, M. Hatton, S. Kernaghan, J. Lanchbury, J. Morden, J. Owen, J. Parikh, P. Parker, N. Rahman, R. Roylance, A. Shaw, I. Smith, Roxanna Thompson, K. Timms, H. Tovey, A. Wardley, G. Wilson, M. Harries, J. Bliss (2015)
Abstract S3-01: The TNT trial: A randomized phase III trial of carboplatin (C) compared with docetaxel (D) for patients with metastatic or recurrent locally advanced triple negative orBRCA1/2breast cancer (CRUK/07/012)Cancer Research, 75
-
S. Mahmoud, E. Paish, D. Powe, R. Macmillan, M. Grainge, Andrew Lee, I. Ellis, A. Green (2011)
Tumor-infiltrating CD8+ lymphocytes predict clinical outcome in breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 29 15
-
R. Dent, M. Trudeau, K. Pritchard, W. Hanna, H. Kahn, C. Sawka, L. Lickley, E. Rawlinson, P. Sun, S. Narod (2007)
Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 13
-
A. Prat, J. Parker, O. Karginova, C. Fan, C. Livasy, Jason Herschkowitz, Xiaping He, C. Perou (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research : BCR, 12
-
G. Minckwitz, C. Fontanella (2013)
Selecting the neoadjuvant treatment by molecular subtype: how to maximize the benefit?Breast, 22 Suppl 2
-
C. Liedtke, C. Mazouni, K. Hess, F. André, A. Tordai, J. Mejia, W. Symmans, A. González-Angulo, B. Hennessy, Marjorie Green, M. Cristofanilli, G. Hortobagyi, L. Pusztai (2008)
Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 8
-
Xiao-song Chen, Ying Yuan, D. Garfield, Jiayi Wu, O. Huang, K. Shen (2014)
Both Carboplatin and Bevacizumab Improve Pathological Complete Remission Rate in Neoadjuvant Treatment of Triple Negative Breast Cancer: A Meta-AnalysisPLoS ONE, 9
-
B. Lehmann, J. Pietenpol (2014)
Identification and use of biomarkers in treatment strategies for triple‐negative breast cancer subtypesThe Journal of Pathology, 232
-
Nicolai Birkbak, Zhigang Wang, Ji-Young Kim, A. Eklund, Qiyuan Li, Ruiyang Tian, Christian Bowman-Colin, Yang Li, April Greene-Colozzi, J. Iglehart, N. Tung, Paula Ryan, Judy Garber, D. Silver, Z. Szallasi, Andrea Richardson (2012)
Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.Cancer discovery, 2 4
-
M. Dieci, M. Dieci, C. Criscitiello, A. Goubar, G. Viale, P. Conte, V. Guarneri, G. Ficarra, M. Mathieu, S. Delaloge, G. Curigliano, F. André (2014)
Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study.Annals of oncology : official journal of the European Society for Medical Oncology, 25 3
-
M. Telli, K. Jensen, S. Vinayak, A. Kurian, J. Lipson, P. Flaherty, K. Timms, V. Abkevich, E. Schackmann, I. Wapnir, R. Carlson, Pei-Jen Chang, J. Sparano, Bobbie Head, L. Goldstein, B. Haley, S. Dakhil, J. Reid, A. Hartman, J. Manola, J. Ford (2015)
Phase II Study of Gemcitabine, Carboplatin, and Iniparib As Neoadjuvant Therapy for Triple-Negative and BRCA1/2 Mutation-Associated Breast Cancer With Assessment of a Tumor-Based Measure of Genomic Instability: PrECOG 0105.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
-
S. Isakoff, E. Mayer, Lei He, T. Traina, L. Carey, K. Krag, H. Rugo, Minetta Liu, V. Stearns, S. Come, K. Timms, A. Hartman, D. Borger, D. Finkelstein, J. Garber, P. Ryan, E. Winer, P. Goss, L. Ellisen (2015)
TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 17
-
A. Shinde, J. Zhai, K. Yu, P. Frankel, J. Yim, T. Luu, L. Kruper, C. Vito, S. Shaw, N. Vora, Michele Kirschenbaum, G. Somlo (2015)
Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab.Breast, 24 1
-
M. Laé, P. Fréneaux, X. Sastre-Garau, Olfa Chouchane, B. Sigal‐Zafrani, A. Vincent-Salomon (2009)
Secretory breast carcinomas with ETV6-NTRK3 fusion gene belong to the basal-like carcinoma spectrumModern Pathology, 22
-
GJ Morris, S Naidu, AK Topham, F Guiles, Y Xu, P McCue (2007)
Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute’s Surveillance, Epidemiology, and End Results databaseCancer, 110
-
E. Montagna, P. Maisonneuve, N. Rotmensz, G. Cancello, M. Iorfida, A. Balduzzi, V. Galimberti, P. Veronesi, A. Luini, G. Pruneri, L. Bottiglieri, M. Mastropasqua, A. Goldhirsch, G. Viale, M. Colleoni (2013)
Heterogeneity of triple-negative breast cancer: histologic subtyping to inform the outcome.Clinical breast cancer, 13 1
-
V. Abkevich, K. Timms, B. Hennessy, J. Potter, M. Carey, L. Meyer, K. Smith-McCune, R. Broaddus, K. Lu, Jian Chen, Thanh Tran, Dominic Williams, D. Iliev, Srikanth Jammulapati, Lisa Fitzgerald, T. Krivak, J. Deloia, A. Gutin, G. Mills, J. Lanchbury (2012)
Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancerBritish Journal of Cancer, 107
-
V. Kaklamani, J. Jeruss, Elisha Hughes, K. Siziopikou, K. Timms, A. Gutin, V. Abkevich, Zaina Sangale, C. Solimeno, K. Brown, Joshua Jones, A. Hartman, Caitlin Meservey, B. Jovanovic, I. Helenowski, S. Khan, K. Bethke, N. Hansen, Regina Uthe, S. Giordano, S. Rosen, K. Hoskins, J. Roenn, Sarika Jain, V. Parini, W. Gradishar (2015)
Phase II neoadjuvant clinical trial of carboplatin and eribulin in women with triple negative early-stage breast cancer (NCT01372579)Breast Cancer Research and Treatment, 151
-
S Carrick, D Ghersi, N Wilcken, J Simes (2004)
Platinum containing regimens for metastatic breast cancerCochrane Database Syst Rev., 3
-
E. Rakha, M. El-Sayed, A. Green, Andrew Lee, J. Robertson, I. Ellis (2007)
Prognostic markers in triple‐negative breast cancerCancer, 109
-
S. Loi, S. Loi, S. Michiels, S. Michiels, R. Salgado, N. Sirtaine, V. Jose, D. Fumagalli, P. Kellokumpu-Lehtinen, P. Bono, V. Kataja, C. Desmedt, M. Piccart, S. Loibl, C. Denkert, M. Smyth, H. Joensuu, C. Sotiriou (2014)
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial.Annals of oncology : official journal of the European Society for Medical Oncology, 25 8
-
Fatima Cardoso, A. Costa, Larry Norton, D. Cameron, T. Cufer, Lesley Fallowfield, P. Francis, J. Gligorov, S. Kyriakides, Nan Lin, O. Pagani, E. Senkus, Christoph Thomssen, M. Aapro, J. Bergh, A. Leo, N. Saghir, Patricia Ganz, K. Gelmon, A. Goldhirsch, Nadia Harbeck, N. Houssami, C. Hudis, Bella Kaufman, M. Leadbeater, M. Mayer, Alan Rodger, H. Rugo, V. Sacchini, G. Sledge, L. Veer, Giuseppe Viale, I. Krop, E. Winer (2012)
1st International consensus guidelines for advanced breast cancer (ABC 1).Breast, 21 3
-
T. Byrski, J. Gronwald, T. Huzarski, E. Grzybowska, M. Budryk, M. Stawicka, T. Mierzwa, M. Szwiec, R. Wiśniowski, M. Siołek, R. Dent, J. Lubiński, S. Narod (2010)
Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 3
-
W. Sikov, D. Berry, C. Perou, Baljit Singh, C. Cirrincione, S. Tolaney, C. Kuzma, T. Pluard, G. Somlo, E. Port, M. Golshan, J. Bellon, D. Collyar, O. Hahn, L. Carey, C. Hudis, E. Winer (2015)
Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance).Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 1
-
Y. Mao, Q. Qu, Yuzi Zhang, Junjun Liu, Xiao-song Chen, K. Shen (2014)
The Value of Tumor Infiltrating Lymphocytes (TILs) for Predicting Response to Neoadjuvant Chemotherapy in Breast Cancer: A Systematic Review and Meta-AnalysisPLoS ONE, 9
-
L. Hines, B. Risendal, T. Byers, Sarah Mengshol, J. Lowery, Meenakshi Singh (2011)
Ethnic disparities in breast tumor phenotypic subtypes in Hispanic and non-Hispanic white women.Journal of women's health, 20 10
-
Z. Mei, Y. Liu, C. Liu, Alexander Cui, Z. Liang, G. Wang, H. Peng, L. Cui, C. Li (2014)
Tumour-infiltrating inflammation and prognosis in colorectal cancer: systematic review and meta-analysisBritish Journal of Cancer, 110
-
K Bauer, M Brown, R Cress, C Parise, V Caggiano (2007)
Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population based study from the California Cancer RegistryCancer, 109
-
B. Hennessy, S. Krishnamurthy, S. Giordano, T. Buchholz, S. Kau, Z. Duan, V. Valero, G. Hortobagyi (2005)
Squamous cell carcinoma of the breast.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 23 31
-
M. Vollebergh, E. Lips, P. Nederlof, L. Wessels, L. Wessels, M. Schmidt, E. Beers, S. Cornelissen, M. Holtkamp, F. Froklage, de Vries, J. Schrama, J. Wesseling, M. Vijver, H. Tinteren, M. Bruin, Michael Hauptmann, S. Rodenhuis, Sabine Linn (2010)
An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patientsAnnals of Oncology, 22
-
D. Wetterskog, M. López-García, Maryou Lambros, R. A’Hern, F. Geyer, F. Milanezi, Maria Cabral, R. Natrajan, A. Gauthier, K. Shiu, N. Orr, S. Shousha, Z. Gatalica, A. Mackay, J. Palacios, J. Reis-Filho, B. Weigelt (2012)
Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple‐negative and basal‐like breast cancersThe Journal of Pathology, 226
- Publisher
- Springer Journals
- Copyright
- Copyright © 2015 by Springer Science+Business Media New York
- Subject
- Medicine & Public Health; Oncology; Internal Medicine; Surgical Oncology
- ISSN
- 1943-4588
- eISSN
- 1943-4596
- DOI
- 10.1007/s12609-015-0194-z
- Publisher site
- See Article on Publisher Site
Abstract
Triple-negative breast cancer (TNBC) is a heterogeneous disease with different biological characteristics and treatment outcomes compared to other subtypes of breast cancer. Recently, platinum-based chemotherapy has received increased attention in TNBCs based on promising results especially in the neoadjuvant setting. Homologous recombination deficiency (HRD) and tumor infiltrating lymphocytes (TILs) are new emerging biomarkers associated with platinum efficacy. Despite heterogeneity of methods used for HRD assessment, results of published studies showed consistently the predictive value of HRD for efficacy of platinum-based chemotherapy, especially in the neoadjuvant setting. Prognostic value of TILs in TNBCs is consistent across the trials and while the predictive value of TILs for platinum-based therapy in TNBCs is promising, it needs to be confirmed in further trials. Further research should focus on prospective validation of these biomarkers to confirm their clinical utility, while combination of these markers could lead to composite biomarkers that mirror both tumor and microenvironment properties.
Journal
Current Breast Cancer Reports – Springer Journals
Published: Oct 1, 2015